FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
Stigmatizing language on transplant websites may deter patients with alcohol use disorder and alcohol-associated liver disease from seeking necessary medical care.
Investigators may have uncovered a new factor contributing to the rising incidence of metabolic dysfunction–associated steatotic liver disease among Latinx pediatric patients.